GERN
NASDAQ · Biotechnology
Geron Corp
$1.58
+0.04 (+2.60%)
Open$1.55
Previous Close$1.54
Day High$1.60
Day Low$1.53
52W High$2.01
52W Low$1.04
Volume—
Avg Volume13.16M
Market Cap926.10M
P/E Ratio—
EPS$-0.13
SectorBiotechnology
Analyst Ratings
Buy
13 analysts
Price Target
+1,103.2% upside
Current
$1.58
$1.58
Target
$19.01
$19.01
$12.94
$19.01 avg
$24.33
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 161.66M | 153.95M | 141.15M |
| Net Income | -73,443,225 | -36,660,557 | -32,364,939 |
| Profit Margin | -45.4% | -23.8% | -22.9% |
| EBITDA | -60,196,482 | -44,322,691 | -40,350,825 |
| Free Cash Flow | — | -25,979,960 | -28,291,864 |
| Rev Growth | +574.2% | +15.1% | +6.9% |
| Debt/Equity | 1.10 | 0.42 | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |